New Study “Antibody-Drug Conjugates 2011” Now Available at MarketPublishers.com29 Sep 2011 • by Natalie Aster
LONDON – The stakeholders in the field of ADC have shown true interest and enthusiasm about the recent approval of Seattle Genetics’ antibody-drug conjugate Adcetris. Rising approval had its grounds in stunning tumor response rates in relapsed Hodgkin’s lymphoma and anaplastic large cell lymphoma. Healthy and large-scale sales rates of the expensive therapy are expected by the specialists. However, the FDA request post-approval studies indicating that the high response rates translate into improved survival rate.
New market research report “Antibody-Drug Conjugates 2011” worked out by La Merie provides a compilation of data and information about antibody-drug conjugate companies, technologies and products in R&D. An all-covering analysis of the state of the art and key trends is featured along with detailed appraisal of the clinical results of active and discontinued ADC projects and products. Key stakeholders and their contribution to the growth ADC technology and products is reviewed.
Title: Antibody-Drug Conjugates 2011 - real breakthrough still to come. A Technology, Stakeholder and R&D Pipeline Analysis
Published: September, 2011
Price: US$ 2,632
3. EXECUTIVE SUMMARY
4. DRUGS AND LINKERS USED IN ANTIBODY-DRUG CONJUGATES
5. ANTIBODIES USED IN ANTIBODY-DRUG CONJUGATES
6. ANALYSIS OF STAKEHOLDERS IN ANTIBODY-DRUG CONJUGATES
7. CLINICAL VALUE OF ANTIBODY-DRUG CONJUGATES
8. R&D PIPELINE ANALYSIS OF ANTIBODY-DRUG CONJUGATES
9. COMMERCIAL VALUES OF ANTIBODY-DRUG CONJUGATES
10. COMPANY PROFILES
Alpha Cancer Technologies
Astellas Pharma (Agensys)
Bayer Healthcare Pharmaceuticals
Bristol-Myers Squibb (Medarex)
More new market reports by the publisher can be found at La Merie page.
The Market Publishers, Ltd.
Mrs. Tanya Rezler
Tel: +44 208 123 2220
Fax: +44 207 900 3970